Researchers identify glucose usage as one major divergence betweenT cells expanding in vitro versus those expanding in vivo.
The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...
Novo's blockbuster diabetes drug Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ...
The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...
A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
A team of stem cell scientists have successfully used embryonic stem cell engineering to create a bi-paternal mouse—a mouse ...
Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...
RELATED: Gynecologist Cautions Women About This "Overlooked" Ozempic Side Effect. Scientists found that Ozempic can weaken ...
Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...